Are you Dr. Nwizu?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 25 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
22 S Greene St
Baltimore, MD 21201Phone+1 410-706-4613Fax+1 410-706-4619
Summary
- Dr. Chidi Nwizu, MD is an infectious disease specialist in Baltimore, Maryland. He is currently licensed to practice medicine in Maryland, North Carolina, and Vermont. He is affiliated with University of Maryland Medical Center and is an Assistant Professor at University of Maryland School of Medicine.
Education & Training
- Harlem Hospital CenterResidency, Internal Medicine, 1995 - 1998
- University of Benin Faculty of MedicineClass of 1988
Certifications & Licensure
- VT State Medical License 2016 - 2026
- MS State Medical License 1999 - 2025
- NC State Medical License 2022 - 2025
- OR State Medical License 2014 - 2025
- GA State Medical License 2013 - 2017
- MD State Medical License 2008 - 2015
- UT State Medical License 2006 - 2010
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Infectious Disease
- Join now to see all
Publications & Presentations
PubMed
- HIV Viral Dynamics of Lopinavir/Ritonavir Monotherapy as Second-Line Treatment: A Prospective, Single-Arm Trial.Cassidy W. Claassen, David Keckich, Chidi Nwizu, Alash'le Abimiku, Donald Salami
Journal of the International Association of Providers of AIDS Care. 2019-01-29 - 4 citationsPain Management for Persons Living With HIV Disease: Experience With Interprofessional Education in Nigeria.Carla Alexander, Gregory Pappas, Yvonne Henley, Angela Kaiza Kangalawe, Folaju O Oyebola
The American Journal of Hospice & Palliative Care. 2015-08-01 - 3 citationsRaltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of...Janaki Amin, Mark A Boyd, Nagalingeswaran Kumarasamy, Cecilia L Moore, Marcello H Losso
Plos One. 2015-01-01